Ablation of Perimitral Flutter Following Catheter Ablation of Atrial Fibrillation: Impact on Outcomes

Overview

This prospective, randomized study aims to compare the impact of ablation of perimitral flutter only versus cardioversion and repeat isolation of pulmonary veins with ablation of additional triggers, on procedure outcome.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2011

Detailed Description

Background: In recent years, catheter ablation has been accepted as the treatment-of-choice for drug-refractory atrial fibrillation (AF). It is centered around isolating pulmonary veins (PVs) and its success rate in curing AF is very high (56%-85%) (1). However, despite isolation of this dominant source of triggers, recurrent tachyarrhythmia is the major complication of this procedure with peri-mitral atrial flutter (PMFL) being the most common macro-reentrant arrhythmia in context of AF ablation (2). These often drug-refractory arrhythmias are frequently associated with more severe symptoms than the original AF (3) and warrant the necessity for redo-ablation. This study aims to compare the impact of two different redo-ablation strategies on the procedure outcome; (1) ablation of the perimitral flutter only and (2) cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers. Study method: A total number of 65 AF patients presenting for redo-ablation and PMFL will be randomized to perimitral flutter ablation only or cardioversion and re-isolation (PVI) plus ablation of additional triggers. Additional triggers will be identified with the help of post-ablation drug provocation with isoproterenol. Patients will enter a follow-up period of 12 months after the ablation procedure, when they will be monitored for recurrence of arrhythmia detected either by in-clinic or remote device interrogation at 1, 3, 6 and 12 month post-procedure.

Interventions

  • Procedure: catheter ablation
    • perimitral flutter ablation by blocking the mitral isthmus
  • Procedure: catheter ablation
    • cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers

Arms, Groups and Cohorts

  • Experimental: PMFL ablation
    • Radio-frequency catheter ablation of the mitral isthmus only
  • Experimental: Repeat PVAI and triggers ablation
    • cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers

Clinical Trial Outcome Measures

Primary Measures

  • Freedom from AF/ flutter/ tachycardia off antiarrhythmic therapy
    • Time Frame: 1 year

Secondary Measures

  • Total number of hospitalizations during the study period Change in quality of life
    • Time Frame: 12 months

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with previous AF ablation presenting with PMFL and recurrent AF – Age: 18- 75 years – Willingness and ability to give written informed consent – Therapeutic INR for at least 4 weeks prior to the procedure Exclusion Criteria:

  • Reversible causes of AF such as pericarditis and hyperthyroidism – Documented intra-atrial thrombus, tumor or any other abnormality which prevents easy catheter manipulation – Enrollment in another clinical study – Any other terminal illness

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Texas Cardiac Arrhythmia Research Foundation
  • Provider of Information About this Clinical Study
    • Principal Investigator: Andrea Natale, Executive Medical Director – Texas Cardiac Arrhythmia Research Foundation
  • Overall Official(s)
    • Andrea Natale, MD, Principal Investigator, Texas cardia Arrhythmia Institute, St.David’s Medical center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.